Ms. Xinli Shi | Tumor | Best Researcher Award
Shanxi University of Chinese Medicine | China
AUTHOR PROFILE
π₯MS. XINLI SHI: ACADEMIC AND PROFESSIONAL PROFILE
πEARLY ACADEMIC PURSUITS
Ms. Xinli Shi, a Chinese national, began her academic journey with a B.Sc. in Biochemistry from the Department of Bioengineering at Hebei University of Science and Technology (1996β2001). She deepened her expertise in immunological mechanisms with an M.Sc. in Medical Immunology (2003β2007) from Hebei Medical University, followed by a Ph.D. in Immunology (2011β2014) from the West China College of Basic Medicine and Forensic Medicine, Sichuan Universityβone of China’s top-tier medical schools.
π©ΊPROFESSIONAL ENDEAVORS
Prof. Shi’s academic career spans over two decades, reflecting progressive growth:
-
2001β2013: She served at Hebei Medical University as a Teaching Assistant and then Lecturer, establishing foundational teaching experience.
-
2013β2018: Appointed Associate Professor and Masterβs Supervisor at the School of Basic Medicine, Hebei University of Chinese Medicine.
-
2015β2017: Completed a Postdoctoral Fellowship at the Bethune International Peace Hospital, affiliated with the Third Military Medical University, focusing on advanced clinical research.
-
2018β2023: Promoted to Professor and Doctoral Supervisor at Hebei University of Chinese Medicine.
-
2023βPresent: Serving as Professor and Doctoral/Master Supervisor at the Experimental Management Center, Shanxi University of Chinese Medicine.
π¬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR
Prof. Shi has made notable contributions in the field of tumor immunology, particularly within the tumor microenvironment, focusing on:
-
Autophagy
-
Drug Resistance
-
Restenosis
-
Inflammation-induced tumorigenesis
Her research explores how immune signaling and cellular stress responses shape tumor progression and therapeutic resistance, offering novel targets for immunomodulatory and chemotherapeutic interventions.
She has guided:
-
3 Ph.D. students
-
20+ M.D. students
-
Supervised postdoctoral fellows, actively fostering academic development and translational medicine research.
πIMPACT AND INFLUENCE
Prof. Shi’s work is highly regarded in both Western medicine and Traditional Chinese Medicine (TCM) circles. Her interdisciplinary approach integrates modern immunology with TCM principles, enabling translational applications in cancer and chronic disease therapy. She has been part of numerous provincial and national talent programs, contributing to science policy and medical education reform.
πRESEARCH GRANTS AND FUNDING
Prof. Shi has led 14 research projects, funded by prestigious national and provincial bodies. These include:
-
2 National Natural Science Foundation of China (NSFC) grants (No. 81873112 & 82274315)
-
China Postdoctoral Science Foundation
-
Hebei Natural Science Foundation (multiple years)
-
Shanxi Science and Technology Department
-
Shanxi Provincial Administration of Traditional Chinese Medicine Innovation Team
πΉ Total grant portfolio spans over a decade, supporting basic, translational, and clinical research initiatives.
πLEGACY AND FUTURE CONTRIBUTIONS
Prof. Shiβs career exemplifies academic excellence, clinical relevance, and mentorship. With growing involvement in Shanxiβs TCM innovation programs, she is positioned to pioneer integrative oncology in Chinaβblending evidence-based traditional practices with cutting-edge immunotherapy research. Her future directions include:
-
Building innovation teams
-
Leading multi-center translational studies
-
Expanding doctoral and postdoctoral programs
-
Enhancing international collaborations in cancer research
π§¬CONCLUSION
Prof. Xinli Shi stands at the confluence of biochemistry, medical immunology, and TCM oncology, with over 20 years of academic and clinical experience. Her dedication to tumor biology, immune modulation, and interdisciplinary research continues to shape the landscape of cancer therapeutics in China. As a mentor, scholar, and innovator, she contributes profoundly to the development of next-generation scientists and the advancement of personalized medicine.
RalB promotes lymph node metastasis in tongue squamous cell carcinoma
Authors: Y. Zhang, Yuman; Z. Liu, Zhihan; Y. Yang, Yanguang; L. Jia, Lifeng; X. Shi, Xinli
Journal: Genes and Genomics
Year: 2025
Human umbilical cord mesenchymal stem cells promoted tumor cell growth associated with increased interleukin-18 in hepatocellular carcinoma
Authors: Y. Yang, Yanguang; S. Li, Shenghao; Q. Peng, Qing; Y. Zhang, Yuman; X. Shi, Xinli
Journal: Molecular Biology Reports
Year: 2024
Recent advances in graphitic carbon nitride-based heterojunction for biomedical applications
Authors: R. Jia, Ruilong; C. He, Cheng’en; S. Wang, Shanshan; G. Liao, Guangfu; X. Shi, Xinli
Citations: 3